136 related articles for article (PubMed ID: 35030285)
1. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
Ruiz de Gauna M; Biancaniello F; González-Romero F; Rodrigues PM; Lapitz A; Gómez-Santos B; Olaizola P; Di Matteo S; Aurrekoetxea I; Labiano I; Nieva-Zuluaga A; Benito-Vicente A; Perugorria MJ; Apodaka-Biguri M; Paiva NA; Sáenz de Urturi D; Buqué X; Delgado I; Martín C; Azkargorta M; Elortza F; Calvisi DF; Andersen JB; Alvaro D; Cardinale V; Bujanda L; Banales JM; Aspichueta P
Hepatology; 2022 Dec; 76(6):1617-1633. PubMed ID: 35030285
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
3. The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma.
Correnti M; Cappon A; Pastore M; Piombanti B; Lori G; Oliveira DVPN; Munoz-Garrido P; Lewinska M; Andersen JB; Coulouarn C; Sulpice L; Peraldo Neia C; Cavalloni G; Quarta S; Biasiolo A; Fassan M; Ramazzotti M; Parri M; Recalcati S; di Tommaso L; Campani C; Invernizzi P; Torzilli G; Marra F; Pontisso P; Raggi C
Liver Int; 2022 Jan; 42(1):233-248. PubMed ID: 34478594
[TBL] [Abstract][Full Text] [Related]
4. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines.
Yang J; Sontag D; Gong Y; Minuk GY
Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
Raggi C; Taddei ML; Sacco E; Navari N; Correnti M; Piombanti B; Pastore M; Campani C; Pranzini E; Iorio J; Lori G; Lottini T; Peano C; Cibella J; Lewinska M; Andersen JB; di Tommaso L; Viganò L; Di Maira G; Madiai S; Ramazzotti M; Orlandi I; Arcangeli A; Chiarugi P; Marra F
J Hepatol; 2021 Jun; 74(6):1373-1385. PubMed ID: 33484774
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma.
Pant K; Peixoto E; Richard S; Biswas A; O'Sullivan MG; Giama N; Ha Y; Yin J; Carotenuto P; Salati M; Ren Y; Yang R; Franco B; Roberts LR; Gradilone SA
Hepatology; 2021 Dec; 74(6):3235-3248. PubMed ID: 34322899
[TBL] [Abstract][Full Text] [Related]
9. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
[TBL] [Abstract][Full Text] [Related]
10. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.
Merino-Azpitarte M; Lozano E; Perugorria MJ; Esparza-Baquer A; Erice O; Santos-Laso Á; O'Rourke CJ; Andersen JB; Jiménez-Agüero R; Lacasta A; D'Amato M; Briz Ó; Jalan-Sakrikar N; Huebert RC; Thelen KM; Gradilone SA; Aransay AM; Lavín JL; Fernández-Barrena MG; Matheu A; Marzioni M; Gores GJ; Bujanda L; Marin JJG; Banales JM
J Hepatol; 2017 Jul; 67(1):72-83. PubMed ID: 28237397
[TBL] [Abstract][Full Text] [Related]
11. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma.
Chuaysri C; Thuwajit P; Paupairoj A; Chau-In S; Suthiphongchai T; Thuwajit C
Oncol Rep; 2009 Apr; 21(4):957-69. PubMed ID: 19287994
[TBL] [Abstract][Full Text] [Related]
12. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.
Liu R; Zhao R; Zhou X; Liang X; Campbell DJ; Zhang X; Zhang L; Shi R; Wang G; Pandak WM; Sirica AE; Hylemon PB; Zhou H
Hepatology; 2014 Sep; 60(3):908-18. PubMed ID: 24700501
[TBL] [Abstract][Full Text] [Related]
13. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
14. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
16. CXCR2 signaling might have a tumor-suppressive role in patients with cholangiocarcinoma.
Yamamoto Y; Sugimoto A; Maruo K; Tsujio G; Sera T; Kushiyama S; Nishimura S; Kuroda K; Togano S; Eguchi S; Tanaka R; Kimura K; Amano R; Ohira M; Yashiro M
PLoS One; 2022; 17(4):e0266027. PubMed ID: 35377900
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
[TBL] [Abstract][Full Text] [Related]
18. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling reveals potential targets in cholangiocarcinoma.
Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
